Vident Investment Advisory, LLC Cara Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$2.83 - $4.94 $98,645 - $172,193	34,857 Added 21.87%	194,262 $549,000
Q1 2023 May 15, 2023	BUY	$4.89 - $12.27 $160,303 - $402,235	32,782 Added 25.89%	159,405 $782,000
Q4 2022 Feb 14, 2023	SELL	$8.88 - $12.77 $22,723 - $32,678	-2,559 Reduced 1.98%	126,623 $1.36 Million
Q3 2022 Nov 14, 2022	BUY	$8.24 - $12.56 $70,798 - $107,915	8,592 Added 7.12%	129,182 $1.21 Million
Q2 2022 Aug 15, 2022	BUY	$7.45 - $13.84 $93,929 - $174,494	12,608 Added 11.68%	120,590 $1.1 Million
Q1 2022 May 16, 2022	BUY	$9.94 - $12.65 $463,104 - $589,363	46,590 Added 75.89%	107,982 $1.31 Million
Q4 2021 Feb 14, 2022	BUY	$11.99 - $18.14 $29,279 - $44,297	2,442 Added 4.14%	61,392 $748,000
Q3 2021 Nov 12, 2021	BUY	$11.55 - $16.06 $680,872 - $946,736	58,950 New	58,950 $911,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.